NCT00733356 - The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Attention Deficit/Hyperactivity Disorder

Interventions

DRUG

Vyvanse

Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.

Trial Locations (1)

92697

University of California, Irvine Child Development Center, Irvine